- Home
- KALA vs RLYB Comparison
KALA vs RLYB Comparison
Compare KALA & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- RLYB
- Stock Information
- Founded
- KALA 2009
- RLYB 2018
- Country
- KALA United States
- RLYB United States
- Employees
- KALA N/A
- RLYB N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- KALA Health Care
- RLYB Health Care
- Exchange
- KALA Nasdaq
- RLYB Nasdaq
- Market Cap
- KALA 26.2M
- RLYB 24.1M
- IPO Year
- KALA 2017
- RLYB 2021
- Fundamental
- Price
- KALA $1.67
- RLYB $0.56
- Analyst Decision
- KALA Buy
- RLYB Hold
- Analyst Count
- KALA 3
- RLYB 2
- Target Price
- KALA $31.50
- RLYB N/A
- AVG Volume (30 Days)
- KALA 2.7M
- RLYB 315.1K
- Earning Date
- KALA 11-11-2025
- RLYB 11-06-2025
- Dividend Yield
- KALA N/A
- RLYB N/A
- EPS Growth
- KALA N/A
- RLYB N/A
- EPS
- KALA N/A
- RLYB N/A
- Revenue
- KALA N/A
- RLYB $761,000.00
- Revenue This Year
- KALA N/A
- RLYB N/A
- Revenue Next Year
- KALA N/A
- RLYB N/A
- P/E Ratio
- KALA N/A
- RLYB N/A
- Revenue Growth
- KALA N/A
- RLYB 154.51
- 52 Week Low
- KALA $1.10
- RLYB $0.22
- 52 Week High
- KALA $20.60
- RLYB $1.24
- Technical
- Relative Strength Index (RSI)
- KALA 27.87
- RLYB 50.25
- Support Level
- KALA $1.26
- RLYB $0.48
- Resistance Level
- KALA $1.69
- RLYB $0.60
- Average True Range (ATR)
- KALA 1.14
- RLYB 0.04
- MACD
- KALA -1.93
- RLYB -0.00
- Stochastic Oscillator
- KALA 2.80
- RLYB 47.74
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.